Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $80
Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ: ELVN ) with a Buy and raises the price target from $60 to $80.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.